PYC Therapeutics (ASX:PYC) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PYC 주식 개요

신약 개발 회사인 PYC Therapeutics Limited는 호주에서 RNA 치료제 분야의 약물 솔루션을 발견하고 개발하는 회사입니다.

PYC 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	1/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 9.29% 증가할 것으로 예상됩니다.

위험 분석

수익은 향후 3년간 연평균 17.1% 씩 감소할 것으로 예상됩니다.

지난 1년 동안 주주가 희석되었습니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

PYC Therapeutics Limited 경쟁사

Dimerix

ASX:DXB

AU$305.1m

Imugene

ASX:IMU

AU$409.9m

Clinuvel Pharmaceuticals

ASX:CUV

AU$758.8m

Aroa Biosurgery

ASX:ARX

AU$222.0m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 PYC Therapeutics
과거 주가
현재 주가	AU$0.14
52주 최고치	AU$0.13
52주 최저치	AU$0.052
베타	0.62
11개월 변경	28.57%
3개월 변경 사항	60.71%
1년 변경 사항	145.45%
33년 변화	-12.90%
5년 변화	350.00%
IPO 이후 변화	-48.08%

최근 뉴스 및 업데이트

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Apr 10

Recent updates

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Feb 20

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

Jan 26

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

Dec 22

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Nov 17

주주 수익률

	PYC	AU Biotechs	AU 마켓
7D	28.6%	4.0%	0.6%
1Y	145.5%	4.2%	6.7%

수익률 대 산업: PYC 지난 1년 동안 4.2 %를 반환한 Australian Biotechs 산업을 초과했습니다.

수익률 대 시장: PYC 지난 1년 동안 6.7 %를 반환한 Australian 시장을 초과했습니다.

가격 변동성

Is PYC's price volatile compared to industry and market?
PYC volatility
PYC Average Weekly Movement	11.7%
Biotechs Industry Average Movement	10.5%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	16.1%
10% least volatile stocks in AU Market	3.2%

안정적인 주가: PYC 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: PYC 의 주간 변동성( 12% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2001	n/a	Rohan Hockings	pyctx.com

신약 개발 회사인 PYC Therapeutics Limited는 호주에서 RNA 치료제 분야의 약물 솔루션을 발견하고 개발하는 회사입니다. 이 회사의 전임상 개발 프로그램에는 11형 망막색소변성증 치료제인 VP-001, 상염색체 우성 시신경 위축증 치료제인 PYC-001, 중증 신경발달 장애 치료제인 PYC-002가 있습니다. 또한 신장, 신경 발달, 망막 및 중추 신경계 질환을 위한 프로그램 개발에도 주력하고 있습니다.

PYC Therapeutics Limited 기본 사항 요약

PYC Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
PYC 기본 통계
시가총액	AU$536.60m
수익(TTM)	-AU$21.65m
수익(TTM)	AU$21.24m

29.7x

P/S 비율

-29.1x

P/E 비율

PYC 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
PYC 손익 계산서(TTM)
수익	AU$21.24m
수익 비용	AU$0
총 이익	AU$21.24m
기타 비용	AU$42.89m
수익	-AU$21.65m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.0046
총 마진	100.00%
순이익 마진	-101.90%
부채/자본 비율	0%

PYC 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

PYC 주식 개요

보상

위험 분석

PYC Therapeutics Limited 경쟁사

ASX:DXB

AU$305.1m

ASX:IMU

AU$409.9m

ASX:CUV

AU$758.8m

ASX:ARX

AU$222.0m

가격 내역 및 성능

최근 뉴스 및 업데이트

New major risk - Revenue and earnings growth

Price target decreased by 15% to AU$0.29

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

Recent updates

New major risk - Revenue and earnings growth

Price target decreased by 15% to AU$0.29

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

New minor risk - Share price stability

We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

CEO & Director exercised options to buy AU$1.6m worth of stock.

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Non-Executive Chair of the Board recently bought AU$81k worth of stock

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes

주주 수익률

가격 변동성

회사 소개

PYC Therapeutics Limited 기본 사항 요약

29.7x

-29.1x

수익 및 수익

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease Autosomal Dominant Optic Atrophy